Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Segal Pharma Group is a private Israeli healthcare and pharmaceutical group with decades of operating history in pharmaceutical and medical-device businesses. The group appears to function primarily as a holding and innovation platform that incubates, develops, manufactures, and commercializes healthcare products through affiliated companies. Publicly visible subsidiaries and affiliates include Panaxia in medical cannabis, Epidaris as an innovation hub for pharmaceutical and medical products, and Axecium Therapeutics in plant-, fungi-, and psychedelic-derived therapeutics with novel delivery systems. The group has been described as having more than 40 years of experience and as producing hundreds of pharmaceutical products distributed internationally. Overall, Segal Pharma Group looks less like a single-asset biotech and more like a diversified private pharma/healthcare group with commercial operations and company-building capabilities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Segal Pharma Group.